Background: In this study, we aimed to compare the operative outcomes, postoperative outcomes, stone-free status and complications of SPCNL and MPCNL in infants younger than two years of age.

Methods: We retrospectively analyzed 163 patients younger than two years of age who underwent percutaneous nephrolithotomy (PCNL) in our institution between September 1999 and March 2022. The patients were divided into two groups depending on the tract size. The MPCNL group consisted of 73 patients with a tract of 22 Fr or less, and the SPCNL consisted of 90 patients with a tract greater than 22 Fr.

Results: The median age of 163 patients included in the study was 17.3 (range 7-24) months. Although the median stone size was lower in the SPCNL group, no statistically significant difference was found between the two groups in terms of stone size (p = 0.073). The median operative time was 74.8 min in the MPCNL group and 62.8 min in the SPCNL group, with a statistically significant difference (p = 0.002). Stone free rates (SFR) were 89 % and 90.8 % in the MPCNL and SPCNL groups, and the clinically insignificant residual fragments (CIRF) rates were 11 % and 4.6 %, respectively (p = 0.064). The fluoroscopy time, nephrostomy withdrawal time, and hospitalization stay were similar in the two PCNL groups (p = 0.535, p = 0.253, and p = 0.143, respectively). Postoperative fever was similar in MPCNL and SPCNL groups (p = 0.504). Although bleeding (6.7%-2.7 %) and blood transfusion (3.3%-1.4 %) rates were higher in the SPCNL group, there was no statistically significant difference (p = 0.248 and p = 0.420, respectively). Prolonged urinary leakage occurred in 6 (8.2 %) patients in the MPCNL group and 1 (1.1 %) patient in the SPCNL group, with a statistically significant difference (p = 0.026).

Conclusions: With the development of MPCNL, the use of SPCNL in infants has decreased considerably. However, SPCNL continues to be an effective and reliable method when needed in suitable patients. Although PCNL in infants shows some differences from adults, it is an effective and safe method for suitable patients.

Level Of Evidence: Although we created our study by retrospectively examining the pediatric urology data that we created prospectively, our study is of a retrospective nature. Therefore the Level of Evidence is 3.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpurol.2023.12.004DOI Listing

Publication Analysis

Top Keywords

spcnl group
16
group statistically
16
statistically difference
16
percutaneous nephrolithotomy
12
mpcnl group
12
mpcnl spcnl
12
spcnl
10
effective safe
8
infants younger
8
younger years
8

Similar Publications

One advantage of supine percutaneous nephrolithotomy (sPCNL) is the ability to access anterior as well as posterior calyces, but the safety and efficacy of anterior calyceal entry has never been investigated to our knowledge. We prospectively evaluated patients scheduled for sPCNL comparing anterior and posterior calyceal access. After Institutional Review Board approval, we prospectively enrolled 100 consecutive patients undergoing sPCNL from February to September 2023.

View Article and Find Full Text PDF
Article Synopsis
  • - Over the last 30 years, miniaturized percutaneous nephrolithotomy (mPCNL) has gained popularity due to its potential to reduce complications compared to standard procedures, but there's still debate over best practices and management strategies that hinders wider use.
  • - An international panel of urology experts developed a consensus document on mPCNL to provide a comprehensive framework for practice, which included reviewing literature, identifying research gaps, and conducting surveys to gather expert opinions.
  • - The study revealed 58 key questions on mPCNL practices, and consensus was achieved on 30 questions, affirming mPCNL as an effective technique for treating upper urinary tract stones in both adults and children.
View Article and Find Full Text PDF

[Efficacy and safety of mini-track, mini-nephroscopy and mini-ultrasonic probe percutaneous nephrolithotomy for the treatment of 1.5-2.5 cm kidney stones].

Beijing Da Xue Xue Bao Yi Xue Ban

August 2024

Department of Urology, Peking University People's Hospital; The Institute of Applied Lithotripsy Technology, Peking University, Beijing 100044, China.

Article Synopsis
  • The study evaluated the effectiveness and safety of a new method called 3mPCNL for treating 1.5-2.5 cm kidney stones, comparing it with the standard method, sPCNL.
  • Researchers analyzed data from 25 patients who underwent 3mPCNL at Peking University People's Hospital, looking at factors like operation time, stone-free rates, and complications.
  • Results showed no major differences in most preoperative factors between the two groups, and while operation time was similar, there were significant changes in hemoglobin levels in the sPCNL group post-surgery.
View Article and Find Full Text PDF
Article Synopsis
  • Supine percutaneous nephrolithotomy (s-PCNL) is being evaluated for its safety and effectiveness in treating renal pelvis stones in Malaysia, involving a study of 115 patients from November 2020 to May 2023.
  • The study found that single middle calyceal renal access (MCA) had a higher stone-free rate compared to other access methods, with very few major complications or need for blood transfusions.
  • The results suggest that s-PCNL is a safe and efficient treatment, particularly for patients undergoing additional endourological procedures, with an average hospital stay of about 2.9 days.
View Article and Find Full Text PDF

Purpose: To assess the safety and efficacy of super-mini PCNL (SMP, 14 Fr) when compared to standard PCNL (sPCNL, 24-30 Fr) in the management of renal calculi of size ranging from 1.5 to 3 cm.

Methods: From February 2021 to January 2022, a total of 100 patients were randomized to either SMP group or sPCNL group in a 1:1 ratio (50 in each group) using computer-generated simple randomization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!